Stock Track | GENSCRIPT BIO Soars 5.05% Intraday as AI Drug Discovery Commercialization and CARVYKTI Sales Surge

Stock Track

Aug 11

GENSCRIPT BIO (01548) soared 5.05% in intraday trading, extending its recent strong momentum as investors reacted to multiple positive catalysts in the AI-driven drug discovery and cell therapy sectors.

Global AI-driven drug discovery is increasingly moving into the commercialization phase, with US-listed Twist Bioscience reporting mid-year results that beat expectations and AI-related orders doubling year-over-year. GENSCRIPT BIO’s life sciences division, which covers DNA synthesis, protein production, antibody development, and functional validation, is positioned as a key infrastructure provider for converting AI-generated sequences into physical proteins and experimental data. The division recorded revenue of USD 522 million, up 14.8% year-over-year, reinforcing its role in the AI drug discovery ecosystem.

Additionally, GENSCRIPT BIO’s associate Legend Biotech reported strong CARVYKTI sales, with Q2 net trade sales of USD 657 million, a 49.4% year-over-year increase, and first-half sales reaching USD 1.254 billion, up 55.1%. The company is also set to hold a board meeting on August 15 to review interim results and dividend arrangements, further boosting market expectations.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/news/1135091676"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1135091676\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1135091676?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-11 10:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1135091676","market":"nz","top_or_hot":-1,"title":"Stock Track | GENSCRIPT BIO Soars 5.05% Intraday as AI Drug Discovery Commercialization and CARVYKTI Sales Surge","media":"Stock Track","content":"<p>GENSCRIPT BIO (01548) soared 5.05% in intraday trading, extending its recent strong momentum as investors reacted to multiple positive catalysts in the AI-driven drug discovery and cell therapy sectors.</p><p>Global AI-driven drug discovery is increasingly moving into the commercialization phase, with US-listed Twist Bioscience reporting mid-year results that beat expectations and AI-related orders doubling year-over-year. GENSCRIPT BIO’s life sciences division, which covers DNA synthesis, protein production, antibody development, and functional validation, is positioned as a key infrastructure provider for converting AI-generated sequences into physical proteins and experimental data. The division recorded revenue of USD 522 million, up 14.8% year-over-year, reinforcing its role in the AI drug discovery ecosystem.</p><p>Additionally, GENSCRIPT BIO’s associate Legend Biotech reported strong CARVYKTI sales, with Q2 net trade sales of USD 657 million, a 49.4% year-over-year increase, and first-half sales reaching USD 1.254 billion, up 55.1%. The company is also set to hold a board meeting on August 15 to review interim results and dividend arrangements, further boosting market expectations.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | GENSCRIPT BIO Soars 5.05% Intraday as AI Drug Discovery Commercialization and CARVYKTI Sales Surge</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | GENSCRIPT BIO Soars 5.05% Intraday as AI Drug Discovery Commercialization and CARVYKTI Sales Surge\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-08-11 10:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>GENSCRIPT BIO (01548) soared 5.05% in intraday trading, extending its recent strong momentum as investors reacted to multiple positive catalysts in the AI-driven drug discovery and cell therapy sectors.</p><p>Global AI-driven drug discovery is increasingly moving into the commercialization phase, with US-listed Twist Bioscience reporting mid-year results that beat expectations and AI-related orders doubling year-over-year. GENSCRIPT BIO’s life sciences division, which covers DNA synthesis, protein production, antibody development, and functional validation, is positioned as a key infrastructure provider for converting AI-generated sequences into physical proteins and experimental data. The division recorded revenue of USD 522 million, up 14.8% year-over-year, reinforcing its role in the AI drug discovery ecosystem.</p><p>Additionally, GENSCRIPT BIO’s associate Legend Biotech reported strong CARVYKTI sales, with Q2 net trade sales of USD 657 million, a 49.4% year-over-year increase, and first-half sales reaching USD 1.254 billion, up 55.1%. The company is also set to hold a board meeting on August 15 to review interim results and dividend arrangements, further boosting market expectations.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01548","symbol_name":"金斯瑞生物科技","start_time":0,"source_url":"","article_id":"1135091676","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1135091676","pubTimestamp":1786413630,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"GENSCRIPT BIO (01548) soared 5.05% in intraday trading, extending its recent strong momentum as investors reacted to multiple positive catalysts in the AI-driven drug discovery and cell therapy...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01548":"金斯瑞生物科技"},"translate_title":"股票追踪|金斯瑞生物盘中飙升5.05%，人工智能药物发现商业化和CARVYKTI销量激增","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01548":1},"content_text":"GENSCRIPT BIO (01548) soared 5.05% in intraday trading, extending its recent strong momentum as investors reacted to multiple positive catalysts in the AI-driven drug discovery and cell therapy sectors.Global AI-driven drug discovery is increasingly moving into the commercialization phase, with US-listed Twist Bioscience reporting mid-year results that beat expectations and AI-related orders doubling year-over-year. GENSCRIPT BIO’s life sciences division, which covers DNA synthesis, protein production, antibody development, and functional validation, is positioned as a key infrastructure provider for converting AI-generated sequences into physical proteins and experimental data. The division recorded revenue of USD 522 million, up 14.8% year-over-year, reinforcing its role in the AI drug discovery ecosystem.Additionally, GENSCRIPT BIO’s associate Legend Biotech reported strong CARVYKTI sales, with Q2 net trade sales of USD 657 million, a 49.4% year-over-year increase, and first-half sales reaching USD 1.254 billion, up 55.1%. The company is also set to hold a board meeting on August 15 to review interim results and dividend arrangements, further boosting market expectations.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}